TY - JOUR A1 - Trebing, J. A1 - El-Mesery, M. A1 - Schäfer, V. A1 - Weisenberger, D. A1 - Siegmund, D. A1 - Silence, K. A1 - Wajant, H. T1 - CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants JF - Cell Death & Disease N2 - To combine the CD27 stimulation inhibitory effect of blocking CD70 antibodies with an antibody-dependent cellular cytotoxicity (ADCC)-independent, cell death-inducing activity for targeting of CD70-expressing tumors, we evaluated here fusion proteins of the apoptosis-inducing TNF family member TRAIL and a single-chain variable fragment (scFv) derived from a high-affinity llama-derived anti-human CD70 antibody (lαhCD70). A fusion protein of scFv:lαhCD70 with TNC-TRAIL, a stabilized form of TRAIL, showed strongly enhanced apoptosis induction upon CD70 binding and furthermore efficiently interfered with CD70-CD27 interaction. Noteworthy, introduction of recently identified mutations that discriminate between TRAILR1 and TRAILR2 binding into the TRAIL part of scFv:lαhCD70-TNC-TRAIL resulted in TRAIL death receptor-specific fusion proteins with CD70-restricted activity. KW - apoptosis KW - CD27 KW - CD70 KW - scFv KW - TRAIL Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120078 VL - 5 ER - TY - JOUR A1 - Schlereth, Katharina A1 - Heyl, Charlotte A1 - Krampitz, Anna-Maria A1 - Mernberger, Marco A1 - Finkernagel, Florian A1 - Scharfe, Maren A1 - Jarek, Michael A1 - Leich, Ellen A1 - Rosenwald, Andreas A1 - Stiewe, Thorsten T1 - Characterization of the p53 Cistrome - DNA Binding Cooperativity Dissects p53's Tumor Suppressor Functions JF - PLOS Genetics N2 - p53 protects us from cancer by transcriptionally regulating tumor suppressive programs designed to either prevent the development or clonal expansion of malignant cells. How p53 selects target genes in the genome in a context-and tissue-specific manner remains largely obscure. There is growing evidence that the ability of p53 to bind DNA in a cooperative manner prominently influences target gene selection with activation of the apoptosis program being completely dependent on DNA binding cooperativity. Here, we used ChIP-seq to comprehensively profile the cistrome of p53 mutants with reduced or increased cooperativity. The analysis highlighted a particular relevance of cooperativity for extending the p53 cistrome to non-canonical binding sequences characterized by deletions, spacer insertions and base mismatches. Furthermore, it revealed a striking functional separation of the cistrome on the basis of cooperativity; with low cooperativity genes being significantly enriched for cell cycle and high cooperativity genes for apoptotic functions. Importantly, expression of high but not low cooperativity genes was correlated with superior survival in breast cancer patients. Interestingly, in contrast to most p53-activated genes, p53-repressed genes did not commonly contain p53 binding elements. Nevertheless, both the degree of gene activation and repression were cooperativity-dependent, suggesting that p53-mediated gene repression is largely indirect and mediated by cooperativity-dependently transactivated gene products such as CDKN1A, E2F7 and non-coding RNAs. Since both activation of apoptosis genes with non-canonical response elements and repression of pro-survival genes are crucial for p53's apoptotic activity, the cistrome analysis comprehensively explains why p53-induced apoptosis, but not cell cycle arrest, strongly depends on the intermolecular cooperation of p53 molecules as a possible safeguard mechanism protecting from accidental cell killing. KW - cell-cycle arrest KW - gene expression KW - breast cancer KW - human genome KW - transcriptional repression KW - consensus DNA KW - in-vivo KW - apoptosis KW - network KW - damage Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127579 SN - 1553-7404 VL - 9 IS - 8 ER - TY - THES A1 - Heinze, Britta T1 - Charakterisierung der angeborenen Immunantwort gegen Pneumoviren in einem in vivo Modell T1 - Characterization of the innate immune response against pneumoviruses in an in vivo model N2 - In dieser Arbeit wurde das PVM-Mausmodell verwendet, um die Bedeutung der Typ I und Typ III Interferonantwort für die Pathogenese einer pneumoviralen Infektion zu analysieren. Hierzu wurden zunächst mit Hilfe der reversen Genetik rekombinante PVM-Mutanten hergestellt, bei denen die Gene für die NS-Proteine, welche vermutlich als Interferonantagonisten fungieren, deletiert sind. Die Charakterisierung der Replikationsfähigkeit der rPVM dNS-Mutanten erfolgte in vitro in Interferon-kompetenten und Interferon-inkompetenten Zelllinien. Ein zentraler Schritt innerhalb dieser Charakterisierung war die Untersuchung der Induktion von Interferonen in vivo und in vitro nach Infektion mit den rPVM dNSMutanten, wobei nachgewiesen wurde, dass die NS-Proteine von PVM als Interferonantagonisten fungieren. In allen Interferon-kompetenten Zellkulturen wurde eine Attenuierung von rPVM dNS1, rPVM dNS2 und rPVM dNS1dNS2 bezogen auf rPVM beobachtet. In allen Interferon-inkompetenten Zellkulturen konnte die Attenuierung der rPVM dNS-Mutanten nahezu vollständig revertiert werden. Nach Infektion mit den rPVM dNS-Mutanten wurde in verschiedenen Zelllinien eine Induktion von Typ I und Typ III Interferonen betrachtet, wobei Unterschiede in der Stärke der Interferon-Induktion nach Infektion mit den rPVM dNS-Mutanten vorhanden waren. Zusammenfassend war es möglich, die NS1- und NS2-Proteine von PVM in Analogie zu RSV eindeutig als Antagonisten der Interferonantwort zu identifizieren. Die Untersuchung der protektiven Rolle von Typ I und Typ III Interferonen für die Replikation und Pathogenität von PVM bildete den zweiten Teil dieser Arbeit. Hierzu wurde die Replikationsfähigkeit und Pathogenität der rPVM dNS-Mutanten in verschiedenen Interferon-defizienten Mausstämmen getestet. Die Untersuchungen ergaben eine protektive Rolle von Typ I und Typ III Interferonen bei einer Infektion mit PVM, wobei den Typ I Interferonen ein effektiverer Einfluss zugeordnet werden konnte. Ein Vergleich von Replikation und Virulenz zwischen den verschiedenen Typ I oder Typ III oder Typ I/Typ III Interferonrezeptor-defizienten Mausstämmen belegte eine erhöhte Suszeptibilität der Typ I/Typ III Interferonrezeptor-defizienten Mäuse gegenüber einer Infektion mit den rPVM dNS-Mutanten. Eine vollständige Aufhebung der Attenuierung wurde auch in den Typ I/Typ III Interferonrezeptor-defizienten Mäusen nicht erlangt. Eine anti-apoptotische Funktion der NS-Proteine zusätzlich zu ihrer Wirkungsweise als Interferonantagonisten wurde aufgrund der unvollständigen Revertierung der Pathogenität der rPVM dNS-Mutanten in Typ I/Typ III Interferonrezeptor-defizienten Mäusen vermutet. Der abschließende Teil dieser Dissertation befasste sich mit der Frage, welche Zellen bei einer natürlichen pulmonalen Infektion Interferone in vivo produzieren. In vitro wurde beobachtet, dass überraschenderweise nur sehr wenige virusinfizierte oder uninfizierte Zellen Typ I Interferone bilden. Der Nachweis darüber, welche Zellen während einer pulmonalen Infektion hauptsächlich Interferone in vivo produzieren, war aufgrund der fehlenden Eignung der kommerziell erhältlichen Interferon-Antikörper für intrazelluläre Gewebefärbungen nicht möglich. Dennoch gelang es abschließend durch eine neue Nachweismethode erstmals Zellen mit rezeptorgebundenen Interferon zu identifizieren, wobei es sich um ziliierte Epithelzellen, Alveolarmakrophagen und vermutlich Clarazellen sowie Typ I und Typ II Pneumozyten handelte. N2 - In this thesis the PVM mouse model was used to unveil the role of type I and type III interferone response for the pathogenesis of pneumoviral infection. First, recombinant PVM dNS-mutants with single or combined deletions of the NS-genes were generated and replication efficiency characterization was analyzed in interferon-competent cells as well as in interferon-incompetent cells. A major point was to elucidate the NS-proteins of PVM as interferon antagonists. In interferon-competent cells the replication of rPVM dNS-mutants were significantly attenuated. These attenuation of all three rPVM dNS-mutants was almost completely reversed when interferon-incompetent cells were infected. Induction of type I and type III interferons was determined in different cell types after infection with rPVM dNS-mutants with differences in intensity of interferon induction. Thus, NS1- and NS2-proteins were clearly identified as interferon antagonists. To analyze the protective capacity of type I and type III interferons with respect to replication and pathology of PVM, mice lacking functional receptors for either or both interferons were infected with rPVM or the respective dNS-mutants. The results indicated that both type I and type III interferons which one restricted replication and pathology of PVM, with the former playing the greater role. Interestingly, the replication and virulence of wild-type PVM were completely unaffected by the presence or absence of functional receptors to type I and type III interferon, indicating that both systems are strongly suppressed during infection. However, pretreatment of mice with type I interferon were protective against lethal rPVM challenge, whereas pretreatment with type III interferon delayed but did not prevent death. Finally, the PVM-NS-proteins appeared to delay apoptosis independently of its IFN-antagonistic activity that may contribute to the limited pathogenicity of the viruses in type I/type III receptor deficient mice. In the last part type I interferon producing cells in a pneumoviral infection in vivo should be identified. It was documented that type I interferon producing cells are virusinfected cells as well as uninfected cells. Surprisingly, in vitro only few cells produced type I interferon during rPVM-GFP7 dNS1dNS2 infection. Because the commercially available interferon antibodies are not qualified for intracellular tissue staining it was not possible to identify in vivo the interferon producing cells, but by inventing a new method it was possible to verify the binding of type I interferon to the cell surface receptor of ciliated epithelial cells, alveolar macrophages and presumably Clara cells and type I and type II pneumocytes. KW - Interferon KW - RS-Virus KW - Immunreaktion KW - Lungenentzündung KW - Apoptosis KW - Tiermodell KW - Toll-like-Rezeptoren KW - PVM KW - Nichtstrukturproteine KW - IFNAR KW - Interferonrezeptor KW - PVM KW - interferon KW - IFNAR KW - receptor KW - apoptosis Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-56454 ER - TY - JOUR A1 - Masic, Anita A1 - Valencia Hernandez, Ana Maria A1 - Hazra, Sudipta A1 - Glaser, Jan A1 - Holzgrabe, Ulrike A1 - Hazra, Banasri A1 - Schurigt, Uta T1 - Cinnamic Acid Bornyl Ester Derivatives from Valeriana wallichii Exhibit Antileishmanial In Vivo Activity in Leishmania major-Infected BALB/c Mice JF - PLoS One N2 - Human leishmaniasis covers a broad spectrum of clinical manifestations ranging from self-healing cutaneous leishmaniasis to severe and lethal visceral leishmaniasis caused among other species by Leishmania major or Leishmania donovani, respectively. Some drug candidates are in clinical trials to substitute current therapies, which are facing emerging drug-resistance accompanied with serious side effects. Here, two cinnamic acid bornyl ester derivatives (1 and 2) were assessed for their antileishmanial activity. Good selectivity and antileishmanial activity of bornyl 3-phenylpropanoate (2) in vitro prompted the antileishmanial assessment in vivo. For this purpose, BALB/c mice were infected with Leishmania major promastigotes and treated with three doses of 50 mg/kg/day of compound 2. The treatment prevented the characteristic swelling at the site of infection and correlated with reduced parasite burden. Transmitted light microscopy and transmission electron microscopy of Leishmania major promastigotes revealed that compounds 1 and 2 induce mitochondrial swelling. Subsequent studies on Leishmania major promastigotes showed the loss of mitochondrial transmembrane potential (ΔΨm) as a putative mode of action. As the cinnamic acid bornyl ester derivatives 1 and 2 had exhibited antileishmanial activity in vitro, and compound 2 in Leishmania major-infected BALB/c mice in vivo, they can be regarded as possible lead structures for the development of new antileishmanial therapeutic approaches. KW - leishmania major KW - promastigotes KW - apoptosis KW - mitochondria KW - parasitic diseases KW - leishmania KW - leishmaniasis KW - mouse models Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125354 VL - 10 IS - 11 ER - TY - THES A1 - Lee, Kyeong-Hee T1 - Cofilin T1 - Cofilin N2 - This study has identified cofilin, an actin binding protein, as a control element in the reorganization of the actin cytoskeleton which is highly relevant for T lymphocyte activation. Cofilin is regulated in its activity by reversible phosphorylation which is inducible by stimulation through accessory receptors such as CD2 and CD28. First it could be demonstrated that accessory receptor triggering induces the transient association of cofilin with the actin cytoskeleton and that only the dephosphorylated form of cofilin possesses the capacity to bind cytoskeletal actin in vivo. PI3-kinase inhibitors block both the dephosphorylation of cofilin and its association with the actin cytoskeleton. Importantly, cofilin, actin, PI3-kinase and one of its substrates, namely phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) which can bind to cofilin, co-localize within CD2-receptor caps. The cofilin/F-actin interaction has been identified as a crucial regulatory element for receptor cap formation and the strength of signal transduction. To this end, appropriately designed cell permeable non-toxic peptides that are homologous to actin binding motifs of the human cofilin sequence were introduced into untransformed human peripheral blood T lymphocytes. These peptides competitively and dose dependently inhibit the activation induced interaction of cofilin with the actin cytoskeleton in vivo. By this approach it was possible to study, for the first time, the functional consequences of this interaction in immunocompetent T cells. The present data demonstrate that inhibition of the actin/cofilin interaction in human T lymphocytes by means of these cofilin derived peptides abolishes receptor cap formation and strongly modulates functional T cell responses such as T cell proliferation, interleukin-2 production, cell surface expression of CD69, gIFN production, and CD95L expression. Importantly, receptor independent activation by PMA and calcium ionophore circumvents these peptide produced inhibitory effects on lymphocyte stimulation and places the cofilin/actin interaction to a proximal step in the cascade of signaling events following T cell activation via surface signals. The present results are novel since as yet no information existed regarding the molecular elements which link cell surface receptor stimulation directly to the resulting reorganization of the actin cytoskeleton. N2 - Die vorliegende Arbeit hat gezeigt, dass Cofilin, ein aktin-bindendes Protein, als Kontrollelement bei der Reorganisation des Aktinzytoskeletts fungiert und damit von besonderer Bedeutung für die Aktivierung von T-Lymphozyten ist. Cofilin wird in seiner Aktivität durch reversible Phosphorylierung reguliert, die induzierbar ist über eine Stimulation durch akzessorische Rezeptoren wie CD2 und CD28. Es konnte gezeigt werden, dass eine Stimulation über akzessorische Rezeptoren zu einer transienten Assoziation von Cofilin mit dem Aktinzytoskelett führt und dass nur die dephosphorylierte Form von Cofilin die Fähigkeit besitzt, in vivo an das Aktinzytoskelett zu binden. Inhibitoren der PI3-Kinase blockieren sowohl die Dephosphorylierung von Cofilin, als auch seine Assoziation mit dem Aktinzytoskelett. Hervorzuheben ist, dass Cofilin, zusammen mit Aktin, PI3-Kinase und einem ihrer Substrate, Phosphatidylinositol 4,5-Bisphosphat (PtdIns(4,5)P2), welches an Cofilin binden kann, mit CD2-Rezeptor-"Caps" kolokalisiert. Die Cofilin/F-Aktin-Interaktion konnte als wesentliches regulatorisches Element für die Rezeptor-"Cap"-bildung und die Stärke der Signalübertragung identifiziert werden. Hierzu wurden maßgeschneiderte zellpermeable Peptide, welche homolog zu aktin-bindenden Motiven der humanen Cofilin-Sequenz sind, in nicht-transformierte humane periphere T-Lymphozyten eingeschleust. Diese Peptide hemmen kompetitiv und dosisabhängig die durch Aktivierung induzierte Interaktion von Cofilin mit dem Aktinzytoskelett in vivo. Dieser Ansatz ermöglichte erstmals die Untersuchung funktioneller Konsequenzen dieser Interaktion in immunkompetenten T-Zellen. Die vorgelegten Ergebnissse zeigen, dass die Blockierung der Interaktion von Cofilin mit dem Aktinzytoskelett in humanen T-Zellen mittels von Cofilin abgeleiteter Peptide die Rezeptor-"Cap"-bildung verhindert, sowie zu einer deutlichen Modulation funktioneller T-Zell-Antworten, wie T-Zellproliferation, Interleukin-2-Produktion, Zelloberflächenexpression von CD69, gIFN-Produktion und Expression von CD95L führt. Hervorzuheben ist, dass rezeptor-unabhängige Aktivierung über PMA und Calciumionophor diese durch Peptide verursachten inhibitorischen Effekte umgeht und die Cofilin/Aktin-Interaktion somit als einen proximalen Schritt in der über Oberflächenmoleküle vermittelten Signalübertragungskaskade in T-Zellen identifiziert. Die vorgestellten Ergebnisse sind neu, da bisher keine Informationen bezüglich der molekularen Elemente existierten, welche eine Stimulation von Zelloberflächenrezeptoren direkt mit der Reorganisation des Aktinzytoskeletts verbinden. KW - T-Lymphozyt KW - Aktivierung KW - Actin KW - Cofilin KW - Lymphozytentransformation KW - Cofilin KW - Aktin-Zytoskelett KW - T-Zell-Aktivierung KW - PI3-Kinase KW - Apoptose KW - cofilin KW - actin cytoskeleton KW - T cell activation KW - PI3-kinase KW - apoptosis Y1 - 1999 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-1681 ER - TY - JOUR A1 - Chen, Shasha A1 - Lotz, Christopher A1 - Roewer, Norbert A1 - Broscheit, Jens-Albert T1 - Comparison of volatile anesthetic-induced preconditioning in cardiac and cerebral system: molecular mechanisms and clinical aspects JF - European Journal of Medical Research N2 - Volatile anesthetic-induced preconditioning ( APC) has shown to have cardiac and cerebral protective properties in both pre-clinical models and clinical trials. Interestingly, accumulating evidences demonstrate that, except from some specific characters, the underlying molecular mechanisms of APC-induced protective effects in myocytes and neurons are very similar; they share several major intracellular signaling pathways, including mediating mitochondrial function, release of inflammatory cytokines and cell apoptosis. Among all the experimental results, cortical spreading depolarization is a relative newly discovered cellular mechanism of APC, which, however, just exists in central nervous system. Applying volatile anesthetic preconditioning to clinical practice seems to be a promising cardio- and neuroprotective strategy. In this review, we also summarized and discussed the results of recent clinical research of APC. Despite all the positive experimental evidences, large-scale, long-term, more precisely controlled clinical trials focusing on the perioperative use of volatile anesthetics for organ protection are still needed. KW - APC KW - ischemia-reperfusion injury KW - mitochondria KW - apoptosis Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-175509 VL - 23 IS - 10 ER - TY - JOUR A1 - Bartel, Karin A1 - Pein, Helmut A1 - Popper, Bastian A1 - Schmitt, Sabine A1 - Janaki-Raman, Sudha A1 - Schulze, Almut A1 - Lengauer, Florian A1 - Koeberle, Andreas A1 - Werz, Oliver A1 - Zischka, Hans A1 - Müller, Rolf A1 - Vollmar, Angelika M. A1 - Schwarzenberg, Karin von T1 - Connecting lysosomes and mitochondria – a novel role for lipid metabolism in cancer cell death JF - Cell Communication and Signaling N2 - Background The understanding of lysosomes has been expanded in recent research way beyond their view as cellular trash can. Lysosomes are pivotal in regulating metabolism, endocytosis and autophagy and are implicated in cancer. Recently it was discovered that the lysosomal V-ATPase, which is known to induce apoptosis, interferes with lipid metabolism in cancer, yet the interplay between these organelles is poorly understood. Methods LC-MS/MS analysis was performed to investigate lipid distribution in cells. Cell survival and signaling pathways were analyzed by means of cell biological methods (qPCR, Western Blot, flow cytometry, CellTiter-Blue). Mitochondrial structure was analyzed by confocal imaging and electron microscopy, their function was determined by flow cytometry and seahorse measurements. Results Our data reveal that interfering with lysosomal function changes composition and subcellular localization of triacylglycerids accompanied by an upregulation of PGC1α and PPARα expression, master regulators of energy and lipid metabolism. Furthermore, cardiolipin content is reduced driving mitochondria into fission, accompanied by a loss of membrane potential and reduction in oxidative capacity, which leads to a deregulation in cellular ROS and induction of mitochondria-driven apoptosis. Additionally, cells undergo a metabolic shift to glutamine dependency, correlated with the fission phenotype and sensitivity to lysosomal inhibition, most prominent in Ras mutated cells. Conclusion This study sheds mechanistic light on a largely uninvestigated triangle between lysosomes, lipid metabolism and mitochondrial function. Insight into this organelle crosstalk increases our understanding of mitochondria-driven cell death. Our findings furthermore provide a first hint on a connection of Ras pathway mutations and sensitivity towards lysosomal inhibitors. KW - lysosome KW - V-ATPase KW - mitochondria KW - fission KW - apoptosis KW - lipid metabolism KW - cardiolipin Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-221524 VL - 17 ER - TY - THES A1 - Herold, Marco T1 - Der C-Terminus des antiapoptotischen Bcl-2 Familienmitgliedes A1 reguliert Stabilität und Funktionalität des Proteins T1 - The C-erminus of the antiapoptotic Bcl-2 family member A1 regulates stability and function of the protein N2 - Die Stimulation von Lymphozyten durch alleinige Quervernetzung ihrer Antigenrezeptoren führt in Abhängigkeit von der Signalstärke zur Induktion von Apoptose. Dieser Prozess spielt im Rahmen der negativen Selektion von B-Zellen eine wichtige Rolle und kann am Beispiel von WEHI 231 Zellen, einer murinen Lymphomzelllinie modellhaft nachempfunden werden. Die Quervernetzung des B-Zellrezeptors (BZR) in WEHI 231 Zellen führt in Abhängigkeit von der Prozessierung der mitochondrialen Caspase 9 zu Apoptose. Dies kann durch Überexpression des antiapoptotischen Bcl-2 Familienmitglieds A1 verhindert werden. Interessanterweise besitzt A1 im Gegensatz zu Fast allen anderen Bcl-2 Proteinen keinen C-terminalen Bereich, der das Protein in intrazelluläre Membranen wie Mitochondrien und Endoplasmatisches Retikulum verankert. Ob und gegebenenfalls welche Bedeutung das C-terminale Ende für das Protein und dessen Funktion hat wurde in dieser Arbeit untersucht. Eine C-terminale Deletionsmutante wies im Vergleich zum Wildtyp eine höhere Proteinstabilität auf. Die Fusion der letzten 35 Aminosäuren von A1 an eine enzymatisch inaktive Form von Caspase 3 führte zu einem sehr instabilen chimären Protein. Somit scheint der C-Terminus von A1 sowohl notwendig als auch hinreichend für die kurze Halbwertszeit des Proteins zu sein. Die meisten kurzlebigen Proteine werden über den proteasomalen Signalweg degradiert. Dies scheint auch für A1 zu gelten, da seine Halbwertszeit durch den Einsatz eines Proteasomeninhibitors verlängert wurde. In Koexpressionsstudien konnte zudem eine Ubiquitylierung von A1 beobachtet werden, welche bei der stabileren A1 Mutante stark reduziert war. A1 ist jedoch nicht immer instabil. In Anwesenheit des „BH3-only“ Proteins Bim, das A1 direkt binden kann, wird die Halbwertszeit von A1 enorm erhöht. Die antiapoptotische Funktion von A1 scheint sich jedoch nicht nur auf die Neutralisation durch bloße Bindung zu beschränken, da die Deletionsmutante trotz vergleichbarer Interaktion mit Bim einen sehr viel geringeren Schutz gegen Etoposid vermittelter Apoptose verlieh. Zusammenfassend zeigen die Ergebnisse, dass das antiapoptotische Bcl-2 Familienmitglied A1 eine sehr kurze Halbwertszeit besitzt und das der C-Terminus nicht nur die Stabilität sondern auch die antiapoptotische Schutzfunktion für das Protein vermittelt. N2 - The strong stimulation of lymphocytes through their antigen receptors leads to the induction of apoptosis unless a costimulatory signal is provided. This process plays an important role in the negative selection of B-lymphocytes and can be mimicked in the immature murine lymphoma cell line WEHI 231. Engagement of the B-cell receptor (BCR) on WEHI 231 cells leads to apoptosis via a pathway that requires the processing of mitochondria-dependent caspase 9. This can be prevented by overexpression of the antiapoptotic Bcl-2 family member A1. In contrast to most Bcl-2 proteins, A1 does not contain a C-terminal region which recruits it to intracellular membranes of the mitochondria or endoplasmatic reticulum. The aim of this thesis was to investigate the function of the A1 C-terminus. Deleting the C-terminus increased the stability of A1 whereas fusing the last 35 amino acids of A1 onto an enzymatically-inactive caspase 3 mutant leads to a highly unstable chimeric protein. It therefore appears that the C-terminus is responsible for A1´s short half-life. Most short-lived proteins are degraded via the proteasomal pathway. It is likely A1 is also degraded via the proteasomal pathway, since its half-life was increased in the presence of a proteasomal inhibitor. Furthermore, coexpression studies showed a strong ubiquitylation of A1, which was greatly reduced in the stable truncated variant of A1. However, A1 is not always unstable. In the presence of the ”BH3-only“ protein Bim, a direct interaction partner of A1, the half-life of A1 was strongly increased. The antiapoptotic function of A1 can not just be mediated by the binding and neutralising of proapoptotic partners such as Bim because the C-terminal deletion mutant, which can also interact with Bim, fails to protect cells from etoposide-induced apoptosis. Taken together these results show that the Bcl-2 family member A1 has a very short half life and that the C-terminus is not only responsible for its rapid turnover but also for the antiapoptotic function of the protein. KW - Apoptosis KW - B-Lymphozyten-Rezeptor KW - Inhibitorproteine KW - Apoptose KW - antiapoptotisches Bcl-2 Familienmitglied A1 KW - apoptosis KW - antiapoptotic Bcl-2 family member A1 Y1 - 2005 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-14459 ER - TY - JOUR A1 - Othman, Eman M. A1 - Bekhit, Amany A. A1 - Anany, Mohamed A. A1 - Dandekar, Thomas A1 - Ragab, Hanan M. A1 - Wahid, Ahmed T1 - Design, Synthesis, and Anticancer Screening for Repurposed Pyrazolo[3,4-d]pyrimidine Derivatives on Four Mammalian Cancer Cell Lines JF - Molecules N2 - The present study reports the synthesis of new purine bioisosteres comprising a pyrazolo[3,4-d]pyrimidine scaffold linked to mono-, di-, and trimethoxy benzylidene moieties through hydrazine linkages. First, in silico docking experiments of the synthesized compounds against Bax, Bcl-2, Caspase-3, Ki67, p21, and p53 were performed in a trial to rationalize the observed cytotoxic activity for the tested compounds. The anticancer activity of these compounds was evaluated in vitro against Caco-2, A549, HT1080, and Hela cell lines. Results revealed that two (5 and 7) of the three synthesized compounds (5, 6, and 7) showed high cytotoxic activity against all tested cell lines with IC50 values in the micro molar concentration. Our in vitro results show that there is no significant apoptotic effect for the treatment with the experimental compounds on the viability of cells against A549 cells. Ki67 expression was found to decrease significantly following the treatment of cells with the most promising candidate: drug 7. The overall results indicate that these pyrazolopyrimidine derivatives possess anticancer activity at varying doses. The suggested mechanism of action involves the inhibition of the proliferation of cancer cells. KW - pyrazolo[3,4-d]pyrimidine KW - anticancer activity KW - apoptosis KW - Ki67 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239734 SN - 1420-3049 VL - 26 IS - 10 ER - TY - THES A1 - Grimm, Martin T1 - Die Bedeutung der Expression des Tumornekrosefaktor-alpha bei Patienten mit kolorektalem Karzinom T1 - Tumor Necrosis Factor-α expression in patients with colorectal cancer N2 - Für Tumorprogression müssen entartete Zellen Wege finden, die immunologische Abwehr und die Apoptose zu umgehen. Tumorzellen haben dafür verschiedene, sogenannte Tumor-Escape-Mechanismen entwickelt. Gegenstand dieser Arbeit war in diesem Zusammenhang die Untersuchung des TNF-α-TNF-R1-Systems. Eine signifikante erhöhte TNF-α Protein- und Genexpression konnte in Gewebeproben kolorektaler Karzinome nachgewiesen werden, wobei eine mäßig starke Korrelation beider Analysemethoden ersichtlich war (т = 0.794). Sowohl die immunhistochemische Analyse als auch die Genexpression durch RT-PCR konnten mit Tumorprogression assoziiert werden. Mit erhöhter Expression des Apoptose-induzierenden Zytokins TNF-α durch Tumorzellen konnte darüber hinaus ein signifikant schlechteres Gesamtüberleben der Patienten mit KRK beobachtet werden. In unmittelbarer Umgebung TNF-α exprimierender Tumorzellen wurden zahlreiche TNF-R1+/CD8+ Zellen analysiert, die als Hinweis auf Apoptose in TILs angesehen werden können. Dieser Weg könnte als Tumor-Escape-Mechanismus verstanden werden. Die Verwendung potentieller TNF-α Biologicals (z.B. Etanercept, Infliximab) bleibt jedoch unter dem Aspekt einer geringfügig erhöhten Lymphominzidenz gegenüber der Normalbevölkerung auch als kritisch zu bewerten. Der Einsatz von Anti-TNF-α-Therapien stellt jedoch eine vielversprechende Option bei Patienten mit metastasiertem KRK und Tumorrezidiv dar. Zusammenfassend liefern die Ergebnisse dieser Arbeit zusätzlichen Einblick in die Regulationsmechanismen, die verantwortlich für die Immunsuppression durch kolorektale Karzinome sein können. Diese basiswissenschaftlichen Erkenntnisse stellen eine mögliche Grundlage neuer Behandlungsmöglichkeiten kolorektaler Karzinomen dar, die weiter erforscht werden sollten. N2 - The progressive growth of malignancies is accompanied by a decline in the immune response through mechanisms which are poorly understood. Apoptosis and induction of inflammation by tumor released cytokines as tumor escape mechanisms have been proposed to play an important role in colorectal carcinogenesis. Expression of Tumor necrosis factor-alpha (TNF-α) was analyzed in colorectal cancer specimen by immunohistochemistry and RT-PCR. TNF-α expression on protein and mRNA level were correlated with clinical characteristics and impact on survival. TNFR-1 was co-labelled with TNF-α and CD8+ cytotoxic T cells in immunofluorescence double staining experiments. 94% of the patients with CRC expressed TNF-α. High TNF-α expression was significantly associated with positive lymph node stage and recurrence of the tumor. Multivariate analysis revealed high TNF-α expression as an independent prognostic factor. Immunohistochemistry was correlated with RT-PCR results (т = 0.794). Immunofluorescence double staining experiments revealed increased TNFR-1 expression by CD8+ cells. TNF-α expression by tumor cells may be an efficient immunological escape mechanism by inflammation-enhanced metastases and probably by induction of apoptosis in tumor-infiltrating CD8+ immune cells resulting in a down regulation of the tumoral immune response. Our data support the role of tumor-derived TNF-α expression as an important promoter of tumoral immune escape mechanisms and malignant progression. Targeting TNF-α (e.g. Etanercept, Infliximab) may be a promising option, especially in cases with high TNF-α expression and positive lymph node metastases. KW - Cancer KW - Tumor escape mechanism KW - death receptor signalling KW - apoptosis KW - inflammation KW - colorectal carcinoma Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-52757 ER -